| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $7K | — | +31.3% |
| Operating Income | -$669K | — | -51.2% |
| Net Income | -$663K | — | -60.8% |
| EPS (Basic) | -$1.57 | — | -60.2% |
| EPS (Diluted) | -$1.57 | — | -60.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $18.7M | -6.7% | -17.0% |
| Current Assets | $18.8M | -6.6% | -17.0% |
| Total Assets | $23.8M | -5.3% | -13.9% |
| Current Liabilities | $844K | +70.9% | +50.8% |
| Total Liabilities | $44.1M | -1.5% | +1.9% |
| Stockholders' Equity | -$20.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.3M | — | -173.4% |
| -29.8% |